Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

West Bengal looks to private healthcare investment:

This article was originally published in Clinica

Executive Summary

The West Bengal state government is urging the private sector to take on healthcare and its education to improve access to facilities for "those who can afford it". Dr Surya Kanta Mishra, state minister for health and family welfare, said that this would mean the government could focus on providing "preventive, primary and promotive" healthcare for the poor. Currently, the per capita out-of-pocket medical expenditure in India is double the per capita government spending. It is estimated that the required investment over the next 10 years would be in excess of Rs100,000 crores (US$2bn), reports The Hindu. Investors in the healthcare sector already include the Tata Group, BM Birla (Heart Research Institute) and the Apollo and Parkway Groups (Apollo Gleneagles Hospital).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel